comprehensive -WSS

comprehensive

author：focus 2025-10-01 14:15:41 - browse：297

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： What STAT readers think about the FDA and patient advocacy

WSS

Keeping primary care docs in field isn't impossible, says AAFP CEO

Startling documents reveal new facets of Sacklers' opioid empire

Editas, Vertex strike deal on CRISPR

What STAT readers think about the FDA and patient advocacy

Report: NIH

Average age of first period drops to 11.9 years, study shows

focus

comprehensive

focus

Apple is now the first public company to be valued at $3 trillion

Prosthetic arm enables patients to feel the objects they grip

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Latest bird flu infection made farmworker sicker than earlier cases

In age of alternative facts, a scholarly course on calling out crap

Three trends to watch in biotech in 2024

Alkermes shareholders re

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Dobbs anniversary: the lost opportunity of abortion as health care

First Opinion Podcast: What happens when kids become caregivers?

focus

Hospitals owned by private equity see complications spike 25%

Startling documents reveal new facets of Sacklers' opioid empire

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Virtual care provider acquires bankrupt Pear's prescription apps

Stigma and the return of syphilis

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

hotspot

leisure time

hotspot

entertainment